[
  {
    "title": "之江生物(688317.SH)：实控人已耗资540.56万元增持14万股",
    "href": "http://stock.jrj.com.cn/2022/12/26153737237959.shtml",
    "datetime": "2022-12-26 15:37:04",
    "code": "688317"
  },
  {
    "title": "之江生物：公司抗原产量目前供不应求",
    "href": "http://stock.jrj.com.cn/2022/12/21142937228118.shtml",
    "datetime": "2022-12-21 14:29:11",
    "code": "688317"
  },
  {
    "title": "日均销量增长400多倍！抗原检测概念股全线大涨，之江生物涨15%",
    "href": "http://stock.jrj.com.cn/2022/12/09121637200947.shtml",
    "datetime": "2022-12-09 12:16:33",
    "code": "688317"
  },
  {
    "title": "之江生物：实控人邵俊斌拟增持1000万元-1500万元公司股份",
    "href": "http://stock.jrj.com.cn/2022/11/30180137178783.shtml",
    "datetime": "2022-11-30 18:01:17",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：实控人邵俊斌拟增持1000万元-1500万元的公司股份",
    "href": "http://stock.jrj.com.cn/2022/11/30175737178759.shtml",
    "datetime": "2022-11-30 17:57:04",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：完成回购 累计耗资约1.02亿元回购1.3078%股份",
    "href": "http://stock.jrj.com.cn/2022/11/07173637117593.shtml",
    "datetime": "2022-11-07 17:36:39",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：已累计耗资约1.02亿元回购1.3078%的股份",
    "href": "http://stock.jrj.com.cn/2022/11/02171037106977.shtml",
    "datetime": "2022-11-02 17:10:23",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：一项产品获得国家二类医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/10/10203937045144.shtml",
    "datetime": "2022-10-10 20:39:46",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：全自动核酸提取及检测分析系统获得三类医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/09/20153837007957.shtml",
    "datetime": "2022-09-20 15:38:47",
    "code": "688317"
  },
  {
    "title": "之江生物：公司一项产品获得国家三类医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/09/13111136990580.shtml",
    "datetime": "2022-09-13 11:11:28",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：全自动核酸提取纯化及实时荧光PCR分析系统获得国家三类医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/09/12171036989397.shtml",
    "datetime": "2022-09-12 17:10:26",
    "code": "688317"
  },
  {
    "title": "之江生物(688317)：以集中竞价交易方式回购公司股份",
    "href": "http://stock.jrj.com.cn/2022/09/05091936972570.shtml",
    "datetime": "2022-09-05 09:19:59",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：截至8月底已累计回购1.02%股份",
    "href": "http://stock.jrj.com.cn/2022/08/31174436958772.shtml",
    "datetime": "2022-08-31 17:44:45",
    "code": "688317"
  },
  {
    "title": "之江生物：2022年半年实现营收14.79亿元，同比增长63.12%",
    "href": "http://stock.jrj.com.cn/2022/08/25174236936350.shtml",
    "datetime": "2022-08-25 17:42:33",
    "code": "688317"
  },
  {
    "title": "之江生物：上半年净利4.78亿元 同比增长23.56%",
    "href": "http://stock.jrj.com.cn/2022/08/25163136935781.shtml",
    "datetime": "2022-08-25 16:31:26",
    "code": "688317"
  },
  {
    "title": "之江生物：新型冠状病毒抗原检测试剂盒（胶体金法）获国家三类医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/08/22155436921492.shtml",
    "datetime": "2022-08-22 15:54:22",
    "code": "688317"
  },
  {
    "title": "之江生物：公司接到的海外猴痘核酸检测订单，已进行生产和销售",
    "href": "http://stock.jrj.com.cn/2022/08/17173536908483.shtml",
    "datetime": "2022-08-17 17:35:01",
    "code": "688317"
  },
  {
    "title": "之江生物(688317)：以集中竞价交易方式回购公司股份",
    "href": "http://stock.jrj.com.cn/2022/08/03091536865678.shtml",
    "datetime": "2022-08-03 09:15:36",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：截至7月底已累计回购168.389万股",
    "href": "http://stock.jrj.com.cn/2022/08/02163936863004.shtml",
    "datetime": "2022-08-02 16:39:53",
    "code": "688317"
  },
  {
    "title": "之江生物提示猴痘业务风险，3新股今日申购…重要消息还有这些",
    "href": "http://stock.jrj.com.cn/2022/07/26081636842418.shtml",
    "datetime": "2022-07-26 08:16:00",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：近日公司接到WHO猴痘核酸检测试剂紧急订单",
    "href": "http://stock.jrj.com.cn/2022/07/25195136841123.shtml",
    "datetime": "2022-07-25 19:51:49",
    "code": "688317"
  },
  {
    "title": "A股猴痘概念股开盘强势 之江生物涨近10%",
    "href": "http://stock.jrj.com.cn/2022/07/25093036838957.shtml",
    "datetime": "2022-07-25 09:30:45",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：截至6月底已累计回购112.99万股",
    "href": "http://stock.jrj.com.cn/2022/07/04155236779922.shtml",
    "datetime": "2022-07-04 15:52:56",
    "code": "688317"
  },
  {
    "title": "猴痘概念股集体走强 之江生物和兰卫医学涨超11% 我国开启入境人员猴痘排查",
    "href": "http://stock.jrj.com.cn/2022/07/04112536779204.shtml",
    "datetime": "2022-07-04 11:25:28",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：截至5月底已累计回购13.34万股",
    "href": "http://stock.jrj.com.cn/2022/06/02183036701342.shtml",
    "datetime": "2022-06-02 18:30:38",
    "code": "688317"
  },
  {
    "title": "之江生物：首次回购6万股，支付总金额244万元",
    "href": "http://stock.jrj.com.cn/2022/05/31111736692332.shtml",
    "datetime": "2022-05-31 11:17:57",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：5月30日首次回购6万股",
    "href": "http://stock.jrj.com.cn/2022/05/30192336690652.shtml",
    "datetime": "2022-05-30 19:23:42",
    "code": "688317"
  },
  {
    "title": "之江生物爆炒后热度速降，“猴痘概念股”能吃多久红利？",
    "href": "http://stock.jrj.com.cn/2022/05/27200736685898.shtml",
    "datetime": "2022-05-27 20:07:35",
    "code": "688317"
  },
  {
    "title": "A股异动丨之江生物(688317.SH)涨6.62% 猴痘病毒核酸测定试剂盒已经欧盟CE认证",
    "href": "http://stock.jrj.com.cn/2022/05/24101536672924.shtml",
    "datetime": "2022-05-24 10:15:13",
    "code": "688317"
  },
  {
    "title": "之江生物(688317)：连续3个交易日收盘价格涨幅偏离值累计超过30%",
    "href": "http://stock.jrj.com.cn/2022/05/24085636672634.shtml",
    "datetime": "2022-05-24 08:56:35",
    "code": "688317"
  },
  {
    "title": "【晚间公告全知道】雅戈尔终止向政府捐赠价值13.6亿元资产、之江生物的猴痘病毒核酸测定试剂盒获欧盟CE认证",
    "href": "http://stock.jrj.com.cn/2022/05/23220636671984.shtml",
    "datetime": "2022-05-23 22:06:09",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：猴痘病毒核酸测定试剂盒已经欧盟CE认证",
    "href": "http://stock.jrj.com.cn/2022/05/23215336671982.shtml",
    "datetime": "2022-05-23 21:53:06",
    "code": "688317"
  },
  {
    "title": "猴痘概念股早盘大涨，之江生物一度触及20cm涨停板",
    "href": "http://stock.jrj.com.cn/2022/05/23204536671690.shtml",
    "datetime": "2022-05-23 20:45:50",
    "code": "688317"
  },
  {
    "title": "“猴痘+新冠”双概念加持，20cm涨停之江生物成资本新宠？有公司业绩堪称十年最差！网友灵魂发问咋做到的？",
    "href": "http://stock.jrj.com.cn/2022/05/23180336671010.shtml",
    "datetime": "2022-05-23 18:03:08",
    "code": "688317"
  },
  {
    "title": "之江生物：自主研发生产的猴痘病毒核酸测定试剂盒可助力相关疫病的诊断与防控",
    "href": "http://stock.jrj.com.cn/2022/05/23172836670764.shtml",
    "datetime": "2022-05-23 17:28:51",
    "code": "688317"
  },
  {
    "title": "7连板！这家公司啥情况？“猴痘”概念暴拉，之江生物一度20cm涨停！还有公司预告全年业绩，股价崩了…",
    "href": "http://stock.jrj.com.cn/hotstock/2022/05/23123536669789.shtml",
    "datetime": "2022-05-23 12:35:40",
    "code": "688317"
  },
  {
    "title": "多国发现猴痘病例，相关概念股集体走高，之江生物等大涨",
    "href": "http://stock.jrj.com.cn/2022/05/23103636669437.shtml",
    "datetime": "2022-05-23 10:36:50",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)高开逾15% 猴痘病毒核酸测定试剂盒已有国内外订单",
    "href": "http://stock.jrj.com.cn/2022/05/23093036669190.shtml",
    "datetime": "2022-05-23 09:30:39",
    "code": "688317"
  },
  {
    "title": "之江生物：公司猴痘病毒核酸检测试剂可准确鉴别猴痘病毒",
    "href": "http://stock.jrj.com.cn/2022/05/22205536668612.shtml",
    "datetime": "2022-05-22 20:55:19",
    "code": "688317"
  },
  {
    "title": "之江生物：公司猴痘病毒核酸检测试剂可准确鉴别猴痘病毒",
    "href": "http://stock.jrj.com.cn/2022/05/22203436668602.shtml",
    "datetime": "2022-05-22 20:34:45",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：2021年度权益分派10派13.65元 股权登记日为5月26日",
    "href": "http://stock.jrj.com.cn/2022/05/19182936663039.shtml",
    "datetime": "2022-05-19 18:29:54",
    "code": "688317"
  },
  {
    "title": "之江生物股东宁波睿道减持176.48万股 套现6681.62万 2021年公司净利7.59亿",
    "href": "http://stock.jrj.com.cn/2022/05/16191136652404.shtml",
    "datetime": "2022-05-16 19:11:00",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：减持期届满 宁波睿道已集中竞价减持0.91%股份",
    "href": "http://stock.jrj.com.cn/2022/05/16153536651220.shtml",
    "datetime": "2022-05-16 15:35:39",
    "code": "688317"
  },
  {
    "title": "之江生物拟1亿元-1.8亿元回购股份，用于员工持股计划或者股权激励",
    "href": "http://stock.jrj.com.cn/2022/05/13104436645593.shtml",
    "datetime": "2022-05-13 10:44:01",
    "code": "688317"
  },
  {
    "title": "之江生物将花不超1.8亿元回购公司股份 用于股权激励",
    "href": "http://stock.jrj.com.cn/2022/05/12221136644493.shtml",
    "datetime": "2022-05-12 22:11:57",
    "code": "688317"
  },
  {
    "title": "之江生物等拟回购股份",
    "href": "http://stock.jrj.com.cn/hotstock/2022/05/09074136602142.shtml",
    "datetime": "2022-05-09 07:41:37",
    "code": "688317"
  },
  {
    "title": "之江生物：董事长、实控人提议回购股份，回购金额1亿元-1.8亿元",
    "href": "http://stock.jrj.com.cn/2022/05/07101736586770.shtml",
    "datetime": "2022-05-07 10:17:41",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：拟以1亿元-1.8亿元回购公司股份",
    "href": "http://stock.jrj.com.cn/2022/05/06162036581067.shtml",
    "datetime": "2022-05-06 16:20:18",
    "code": "688317"
  },
  {
    "title": "之江生物2022年第一季度净利2.75亿 同比下滑12.9%",
    "href": "http://stock.jrj.com.cn/2022/05/03191136546527.shtml",
    "datetime": "2022-05-03 19:11:46",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)一季度净利润2.75亿元 同比下降12.9%",
    "href": "http://stock.jrj.com.cn/2022/04/27202436486017.shtml",
    "datetime": "2022-04-27 20:24:04",
    "code": "688317"
  },
  {
    "title": "之江生物披露2021年年报 实现营收20.19亿元",
    "href": "http://stock.jrj.com.cn/2022/04/22092636426313.shtml",
    "datetime": "2022-04-22 09:26:54",
    "code": "688317"
  },
  {
    "title": "之江生物2021年净利7.59亿同比下滑18.61% 董事长邵俊斌薪酬124.5万",
    "href": "http://stock.jrj.com.cn/2022/04/22051236425099.shtml",
    "datetime": "2022-04-22 05:12:58",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)2021年度净利降18.61%至7.59亿元 拟10派13.65元",
    "href": "http://stock.jrj.com.cn/2022/04/21170536419885.shtml",
    "datetime": "2022-04-21 17:05:47",
    "code": "688317"
  },
  {
    "title": "之江生物：自愿披露公司产品获得相关认证",
    "href": "http://stock.jrj.com.cn/2022/04/08105936271320.shtml",
    "datetime": "2022-04-08 10:59:26",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：减持期过半 宁波睿道累计减持376.33万股",
    "href": "http://stock.jrj.com.cn/2022/03/31162436239828.shtml",
    "datetime": "2022-03-31 16:24:19",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：拟使用不超15亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/03/11154234813729.shtml",
    "datetime": "2022-03-11 15:42:45",
    "code": "688317"
  },
  {
    "title": "之江生物股东磐信投资减持714.81万股 套现2.93亿 2021年公司净利7.64亿",
    "href": "http://stock.jrj.com.cn/2022/03/09191134594053.shtml",
    "datetime": "2022-03-09 19:11:32",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：磐信投资近期减持3.67%股份",
    "href": "http://stock.jrj.com.cn/2022/03/09154634544979.shtml",
    "datetime": "2022-03-09 15:46:57",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：磐信投资已累计减持3765.37万股",
    "href": "http://stock.jrj.com.cn/2022/03/07161934537767.shtml",
    "datetime": "2022-03-07 16:19:01",
    "code": "688317"
  },
  {
    "title": "之江生物董事长邵俊斌增持28.81万股 耗资1400.84万 2021年公司净利7.64亿",
    "href": "http://stock.jrj.com.cn/2022/03/01201334509408.shtml",
    "datetime": "2022-03-01 20:13:15",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：增持计划实施完毕 董事长邵俊斌已增持28.81万股",
    "href": "http://stock.jrj.com.cn/2022/03/01170034508500.shtml",
    "datetime": "2022-03-01 17:00:13",
    "code": "688317"
  },
  {
    "title": "A股异动 | 之江生物(688317.SH)跌超5%，2021年度净利同比降18.07%",
    "href": "http://stock.jrj.com.cn/2022/02/22095634433416.shtml",
    "datetime": "2022-02-22 09:56:24",
    "code": "688317"
  },
  {
    "title": "之江生物2021年净利7.64亿同比下滑18.07% 产品毛利下降",
    "href": "http://stock.jrj.com.cn/2022/02/21203234423840.shtml",
    "datetime": "2022-02-21 20:32:52",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)业绩快报：2021年度净利润降18.07%至7.64亿元",
    "href": "http://stock.jrj.com.cn/2022/02/21181034423242.shtml",
    "datetime": "2022-02-21 18:10:52",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：宁波睿道已减持0.56%的股份 持股降至4.99%",
    "href": "http://stock.jrj.com.cn/2022/02/16181334370499.shtml",
    "datetime": "2022-02-16 18:13:31",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：之江科技首次被认定为高新技术企业",
    "href": "http://stock.jrj.com.cn/2022/02/14154434344574.shtml",
    "datetime": "2022-02-14 15:44:55",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：磐信投资通过大宗交易减持5%股份",
    "href": "http://stock.jrj.com.cn/2022/02/11173834324071.shtml",
    "datetime": "2022-02-11 17:38:14",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：磐信投资以大宗交易累计减持4.23%的股份",
    "href": "http://stock.jrj.com.cn/2022/01/19164334174299.shtml",
    "datetime": "2022-01-19 16:43:42",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：公司相关检测产品获得欧盟CE认证",
    "href": "http://stock.jrj.com.cn/2022/01/18181534170547.shtml",
    "datetime": "2022-01-18 18:15:33",
    "code": "688317"
  },
  {
    "title": "之江生物：股东磐信投资拟减持不超5%公司股份",
    "href": "http://stock.jrj.com.cn/2022/01/17200634166179.shtml",
    "datetime": "2022-01-17 20:06:22",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：磐信投资、宁波睿道拟减持合计不超6%股份",
    "href": "http://stock.jrj.com.cn/2022/01/17162534164888.shtml",
    "datetime": "2022-01-17 16:25:47",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：7953.369万股限售股将于1月18日解禁上市",
    "href": "http://stock.jrj.com.cn/2022/01/10192734142482.shtml",
    "datetime": "2022-01-10 19:27:44",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：与复星北铃拟联合开发“全自动P2+核酸检测车”",
    "href": "http://stock.jrj.com.cn/2021/11/22153833903814.shtml",
    "datetime": "2021-11-22 15:38:17",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：人巨细胞病毒(HCMV)核酸测定试剂盒获得欧盟CE认证",
    "href": "http://stock.jrj.com.cn/2021/11/18162633872763.shtml",
    "datetime": "2021-11-18 16:26:14",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)第三季度净利润2.16亿元 同比下降19.33%",
    "href": "http://stock.jrj.com.cn/2021/10/28211533772419.shtml",
    "datetime": "2021-10-28 21:15:11",
    "code": "688317"
  },
  {
    "title": "之江生物2021年前三季度净利6.03亿元 同比净利减少13.34%",
    "href": "http://stock.jrj.com.cn/2021/10/28183033770875.shtml",
    "datetime": "2021-10-28 18:30:31",
    "code": "688317"
  },
  {
    "title": "之江生物前三季度增收反降利，净利润同比降13.34%",
    "href": "http://stock.jrj.com.cn/2021/10/28172333770040.shtml",
    "datetime": "2021-10-28 17:23:25",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：近期获得五项相关认证",
    "href": "http://stock.jrj.com.cn/2021/10/18162933711120.shtml",
    "datetime": "2021-10-18 16:29:11",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：增持金额过半 董事长邵俊斌已增持10.2万股",
    "href": "http://stock.jrj.com.cn/2021/09/17171833452155.shtml",
    "datetime": "2021-09-17 17:18:00",
    "code": "688317"
  },
  {
    "title": "之江生物：实控人兼董事长拟1000万至1500万元增持公司股份",
    "href": "http://stock.jrj.com.cn/2021/08/31131233360687.shtml",
    "datetime": "2021-08-31 13:12:06",
    "code": "688317"
  },
  {
    "title": "之江生物董事长邵俊斌拟增持公司股份 增持股份金额合计不高于1500万 上半年公司净利3.87亿",
    "href": "http://stock.jrj.com.cn/2021/08/30213133355364.shtml",
    "datetime": "2021-08-30 21:31:13",
    "code": "688317"
  },
  {
    "title": "之江生物2021年半年度净利3.87亿元 同比净利减少9.59%",
    "href": "http://stock.jrj.com.cn/2021/08/26183733325644.shtml",
    "datetime": "2021-08-26 18:37:44",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：上半年净利降9.59%至3.87亿元",
    "href": "http://stock.jrj.com.cn/2021/08/26181233325503.shtml",
    "datetime": "2021-08-26 18:12:35",
    "code": "688317"
  },
  {
    "title": "A股异动丨之江生物(688317.SH)涨超8% 已开发能鉴别变异株的产品",
    "href": "http://stock.jrj.com.cn/2021/08/03141633194669.shtml",
    "datetime": "2021-08-03 14:16:29",
    "code": "688317"
  },
  {
    "title": "A股异动丨之江生物(688317.SH)反弹约7% 新冠抗体检测试剂盒获欧盟CE认证",
    "href": "http://stock.jrj.com.cn/2021/07/20143933124024.shtml",
    "datetime": "2021-07-20 14:39:05",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)： 7个相关检测产品获得欧盟CE认证",
    "href": "http://stock.jrj.com.cn/2021/07/19170133119622.shtml",
    "datetime": "2021-07-19 17:01:09",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：186.61万股限售股将于7月19日上市流通",
    "href": "http://stock.jrj.com.cn/2021/07/08170333064728.shtml",
    "datetime": "2021-07-08 17:03:55",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：2020年度拟10派16元 6月7日股权登记",
    "href": "http://stock.jrj.com.cn/2021/06/01165432857385.shtml",
    "datetime": "2021-06-01 16:54:41",
    "code": "688317"
  },
  {
    "title": "大手笔！每10股派16元！之江生物拟派现3.12亿",
    "href": "http://stock.jrj.com.cn/2021/04/22133732422606.shtml",
    "datetime": "2021-04-22 13:37:36",
    "code": "688317"
  },
  {
    "title": "之江生物年度报告：2020年度净利同比增长1709% 拟10派16元",
    "href": "http://stock.jrj.com.cn/2021/04/21171832416851.shtml",
    "datetime": "2021-04-21 17:18:20",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：2020年度净利升1708.96%至9.32亿元 拟10派16元",
    "href": "http://stock.jrj.com.cn/2021/04/21171732416849.shtml",
    "datetime": "2021-04-21 17:17:16",
    "code": "688317"
  },
  {
    "title": "东方投行收警示函 保荐之江生物未充分核查关联交易",
    "href": "http://stock.jrj.com.cn/2021/04/07151632325059.shtml",
    "datetime": "2021-04-07 15:16:00",
    "code": "688317"
  },
  {
    "title": "之江生物获得两项新型冠状病毒检测产品认证",
    "href": "http://stock.jrj.com.cn/2021/03/12093832113830.shtml",
    "datetime": "2021-03-12 09:38:04",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：两项检测产品获得相关认证",
    "href": "http://stock.jrj.com.cn/2021/03/11185932110535.shtml",
    "datetime": "2021-03-11 18:59:07",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：拟使用额度不超15亿元部分暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/03/10181832104752.shtml",
    "datetime": "2021-03-10 18:18:27",
    "code": "688317"
  },
  {
    "title": "之江生物020年度净利9.28亿增长1702% 整体销售规模及业绩呈现大幅增长",
    "href": "http://stock.jrj.com.cn/2021/02/25093532023668.shtml",
    "datetime": "2021-02-25 09:35:33",
    "code": "688317"
  },
  {
    "title": "之江生物业绩快报：2020年净利润9.28亿元 同比增1702%",
    "href": "http://stock.jrj.com.cn/2021/02/24173532019473.shtml",
    "datetime": "2021-02-24 17:35:42",
    "code": "688317"
  },
  {
    "title": "之江生物业绩快报：2020年度净利润9.28亿元 同比增长1702%",
    "href": "http://stock.jrj.com.cn/2021/02/24173032019450.shtml",
    "datetime": "2021-02-24 17:30:43",
    "code": "688317"
  },
  {
    "title": "科创板“新生”之江生物2020年业绩预喜，新冠疫情助提销售规模",
    "href": "http://stock.jrj.com.cn/2021/01/28100831799907.shtml",
    "datetime": "2021-01-28 10:08:56",
    "code": "688317"
  },
  {
    "title": "之江生物2020年预计净利9.3亿增加1705% 销售规模大幅增长",
    "href": "http://stock.jrj.com.cn/2021/01/27184931792027.shtml",
    "datetime": "2021-01-27 18:49:12",
    "code": "688317"
  },
  {
    "title": "之江生物超募6亿上市首日涨73% 曾信披不实身负警示函",
    "href": "http://stock.jrj.com.cn/2021/01/18180531716359.shtml",
    "datetime": "2021-01-18 18:05:00",
    "code": "688317"
  },
  {
    "title": "今日新股上市：之江生物 天能股份",
    "href": "http://stock.jrj.com.cn/2021/01/18091631713023.shtml",
    "datetime": "2021-01-18 09:16:00",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：公司股票1月18日起上市交易",
    "href": "http://stock.jrj.com.cn/2021/01/14191131693320.shtml",
    "datetime": "2021-01-14 19:11:27",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)披露上市发行结果：遭弃购21077股 由主承销商包销",
    "href": "http://stock.jrj.com.cn/2021/01/11223231672609.shtml",
    "datetime": "2021-01-11 22:32:20",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：海通创新证券投资获配146.0282万股 网上摇号中签号共33372个",
    "href": "http://stock.jrj.com.cn/2021/01/07191831649667.shtml",
    "datetime": "2021-01-07 19:18:52",
    "code": "688317"
  },
  {
    "title": "【兑奖啦】科创板之江生物网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2021/01/07191731649661.shtml",
    "datetime": "2021-01-07 19:17:56",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)：网上发行最终中签率为0.03212588%",
    "href": "http://stock.jrj.com.cn/2021/01/06191431643125.shtml",
    "datetime": "2021-01-06 19:14:25",
    "code": "688317"
  },
  {
    "title": "今日新股申购：之江生物",
    "href": "http://stock.jrj.com.cn/2021/01/06085631639277.shtml",
    "datetime": "2021-01-06 08:56:00",
    "code": "688317"
  },
  {
    "title": "之江生物1月6日申购 前三季度净利润6.96亿元",
    "href": "http://stock.jrj.com.cn/2021/01/05184431635835.shtml",
    "datetime": "2021-01-05 18:44:17",
    "code": "688317"
  },
  {
    "title": "科创板新股之江生物1月6日申购宝典",
    "href": "http://stock.jrj.com.cn/ipo/2021/01/05150431634327.shtml",
    "datetime": "2021-01-05 15:04:24",
    "code": "688317"
  },
  {
    "title": "之江生物(688317.SH)首次公开发行不超4867.6088万股 发行价43.22元/股",
    "href": "http://stock.jrj.com.cn/2021/01/04193431628799.shtml",
    "datetime": "2021-01-04 19:34:28",
    "code": "688317"
  },
  {
    "title": "证监会同意奥普特、之江生物、惠泰医疗科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2020/12/08190331442104.shtml",
    "datetime": "2020-12-08 19:03:00",
    "code": "688317"
  },
  {
    "title": "之江生物科创板IPO过会：新冠病毒检测试剂增厚利润 业绩高增长能否持续？ | 产业新股",
    "href": "http://stock.jrj.com.cn/2020/09/25191430836864.shtml",
    "datetime": "2020-09-25 19:14:52",
    "code": "688317"
  },
  {
    "title": "之江生物：今年科创板过会第128家 海通证券过12.5单",
    "href": "http://stock.jrj.com.cn/2020/09/25112930834415.shtml",
    "datetime": "2020-09-25 11:29:00",
    "code": "688317"
  },
  {
    "title": "之江生物改道科创板拟募资增10倍 信披不实身负警示函",
    "href": "http://stock.jrj.com.cn/2020/09/21071130797947.shtml",
    "datetime": "2020-09-21 07:11:00",
    "code": "688317"
  },
  {
    "title": "之江生物、凯因科技9月24日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2020/09/16093130760489.shtml",
    "datetime": "2020-09-16 09:31:00",
    "code": "688317"
  },
  {
    "title": "之江生物2020年上半年净利4.28亿增长1259.16% 销售额增长",
    "href": "http://stock.jrj.com.cn/2020/07/24212130335911.shtml",
    "datetime": "2020-07-24 21:21:52",
    "code": "688317"
  },
  {
    "title": "欲借核酸检测风口募资13亿元 之江生物加速冲关IPO能否如愿",
    "href": "http://stock.jrj.com.cn/kcb/2020/06/24080430006040.shtml",
    "datetime": "2020-06-24 08:04:26",
    "code": "688317"
  },
  {
    "title": "多地支持中医药发展 之江生物等5家企业科创板上市申请获受理 | 医资周报",
    "href": "http://stock.jrj.com.cn/2020/06/05174229853845.shtml",
    "datetime": "2020-06-05 17:42:53",
    "code": "688317"
  },
  {
    "title": "之江生物2019年净利5152.18万下滑17.33% 营业成本增长",
    "href": "http://stock.jrj.com.cn/2020/05/22214629742623.shtml",
    "datetime": "2020-05-22 21:46:15",
    "code": "688317"
  },
  {
    "title": "之江生物向武汉定点捐赠2万人份新型冠状病毒核酸检测试剂及配套设备",
    "href": "http://stock.jrj.com.cn/2020/02/03165428756640.shtml",
    "datetime": "2020-02-03 16:54:00",
    "code": "688317"
  },
  {
    "title": "之江生物任命王凯为公司副总经理 不持有公司股份",
    "href": "http://stock.jrj.com.cn/2020/01/13220128670058.shtml",
    "datetime": "2020-01-13 22:01:13",
    "code": "688317"
  },
  {
    "title": "之江生物董事、副总经理赵洪昇辞职 因个人原因",
    "href": "http://stock.jrj.com.cn/2019/12/24215128581546.shtml",
    "datetime": "2019-12-24 21:51:52",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180127917727.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180130479252.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180131191003.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180132336771.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180133160322.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180133197997.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180127818999.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180130621010.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180128025919.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180130564781.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180131499154.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180131724685.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180132123681.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180129961367.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180131618178.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180133091528.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物收警示函：IPO存少计费用多计收入情形 东方花旗保荐",
    "href": "http://stock.jrj.com.cn/ipo/2019/07/09180133130090.shtml",
    "datetime": "2019-07-09 18:01:00",
    "code": "688317"
  },
  {
    "title": "之江生物拟撤回上市申报材料",
    "href": "http://stock.jrj.com.cn/2018/12/28200726821603.shtml",
    "datetime": "2018-12-28 20:07:00",
    "code": "688317"
  },
  {
    "title": "之江生物2018上半年营收1.03亿元 净利2262万元",
    "href": "http://stock.jrj.com.cn/2018/09/18114425106873.shtml",
    "datetime": "2018-09-18 11:44:00",
    "code": "688317"
  },
  {
    "title": "之江生物IPO申请处于中止审查状态",
    "href": "http://stock.jrj.com.cn/2018/09/17005925097161.shtml",
    "datetime": "2018-09-17 00:59:45",
    "code": "688317"
  },
  {
    "title": "之江生物IPO:三年两次被罚 实控人通过倒手股权日赚2千万",
    "href": "http://stock.jrj.com.cn/ipo/2018/06/06100224644324.shtml",
    "datetime": "2018-06-06 10:02:00",
    "code": "688317"
  },
  {
    "title": "之江生物2017年营收1.93亿元 净赚5121万元",
    "href": "http://stock.jrj.com.cn/2018/04/02154124338701.shtml",
    "datetime": "2018-04-02 15:41:00",
    "code": "688317"
  },
  {
    "title": "之江生物（拟IPO）2017年营收近2亿 净利微增至5121万",
    "href": "http://stock.jrj.com.cn/2018/03/30185224329792.shtml",
    "datetime": "2018-03-30 18:52:00",
    "code": "688317"
  },
  {
    "title": "之江生物9家控参股公司7家亏损 实控人股权转让“搭桥”日赚2000万",
    "href": "http://stock.jrj.com.cn/ipo/2017/12/04013223733441.shtml",
    "datetime": "2017-12-04 01:32:25",
    "code": "688317"
  },
  {
    "title": "【犀说IPO】之江生物：分子诊断龙头跑步赶考IPO",
    "href": "http://stock.jrj.com.cn/2017/08/29185523023702.shtml",
    "datetime": "2017-08-29 18:55:00",
    "code": "688317"
  },
  {
    "title": "之江生物年报推10转10派6元 股权登记日5月31日",
    "href": "http://stock.jrj.com.cn/2016/07/19174421207761.shtml",
    "datetime": "2016-07-19 17:44:00",
    "code": "688317"
  }
]